乙醯水楊酸/辛伐他汀/雷米普利/阿替洛爾/氫氯噻嗪
乙醯水楊酸/辛伐他汀/雷米普利/阿替洛爾/氫氯噻嗪用於預防心血管疾病和中風的口服複方藥[2][4]。具體來說，適用於 10 年內風險超過 10% 的人[1]。對某些人而言，服用一顆複方藥，比單獨服用五種藥更容易[4]。
| 組成 | |
|---|---|
| 乙醯水楊酸 | 抗血小板藥物 |
| 辛伐他汀 | 他汀類藥物 |
| 雷米普利 | 血管緊張素轉換酶抑制劑 |
| 阿替洛爾 | Β受體阻滯劑 |
| 氫氯噻嗪 | 噻嗪類利尿劑 |
| 臨床資料 | |
| 商品名 | Polycap, others[1] |
| 其他名稱 | Aspirin/simvastatin/ramipril/atenolol/hydrochlorothiazide |
副作用由各個成分引起；但一般來說，耐受性良好[3]。該藥物由抗血小板藥物ー乙酰水楊酸（阿司匹林）、他汀類藥物ー辛伐他汀、血管緊張素轉換酶抑制劑ー雷米普利、 β受體阻滯劑ー阿替洛爾和噻嗪類利尿劑ー氫氯噻嗪組成[1]。
此複方製劑已在印度和贊比亞取得醫療使用許可[1]。名列世界衛生組織基本藥物標準清單[5]。
參考文獻
- ^ 1.0 1.1 1.2 1.3 1.4 1.5 An application to include fixed dose combinations in the WHO Model List of Essential Medicines for primary and secondary prevention of atherosclerotic cardiovascular diseases in adults (PDF). WHO. [24 September 2023]. （原始內容存檔 (PDF)於19 October 2023）.
- ^ 2.0 2.1 eEML - Electronic Essential Medicines List. list.essentialmeds.org. [8 September 2023]. （原始內容存檔於10 September 2023）.
- ^ 3.0 3.1 Yusuf, Salim; Pais, Prem; Sigamani, Alben; Xavier, Denis; Afzal, Rizwan; Gao, Peggy; Teo, Koon K. Comparison of Risk Factor Reduction and Tolerability of a Full-Dose Polypill (With Potassium) Versus Low-Dose Polypill (Polycap) in Individuals at High Risk of Cardiovascular Diseases: The Second Indian Polycap Study (TIPS-2) Investigators. Circulation: Cardiovascular Quality and Outcomes. July 2012, 5 (4): 463–471. doi:10.1161/CIRCOUTCOMES.111.963637.
- ^ 4.0 4.1 eEML - Electronic Essential Medicines List. list.essentialmeds.org. [8 September 2023]. （原始內容存檔於9 September 2023）.
- ^ World Health Organization. The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. 2023. WHO/MHP/HPS/EML/2023.02.